



Financial Tear Sheet

Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.



Recent News & Investor Events

10/19/17

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds

10/16/17

Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy

10/05/17

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

There are currently no events scheduled.

SEC Filings

Filing Date	Form	Description
10/03/17	8-K	Report of unscheduled material events or corporate event
10/03/17	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3
10/03/17	4	Statement of changes in beneficial ownership of securities
10/03/17	4	Statement of changes in beneficial ownership of securities